Collaborate With Us

REDEFINING
ORAL PEPTIDE THERAPEUTICS

Clinically validated platform enabling oral delivery
of peptide therapies in obesity, diabetes, and beyond

CLINICALLY VALIDATED

  • ORAL INSULIN – Capsulin™, oral delivery of human insulin preparing for Phase 3
  • WEEKLY ORAL GLP-1 – Oraglutide™, weekly oral GLP-1 RA in Phase 2
  • Microdose oral GLP-1 – Satietyde™, preparing for Phase 2
  • More than 25,000 safe human administrations

PHYSIOLOGY-TARGETED

  • Delivered via the small intestine – direct portal access to the liver and gut receptors
  • Engages the natural physiology of glucose control and satiety
  • Receptor-mediated delivery to the liver, gut and vagal pathways

PLATFORM OPTIONALITY

  • Single platform, multiple peptides – insulin, GLP-1, and combinations
  • Plug-and-play across peptides, with combination therapy capability
  • Demonstrated across insulin and GLP-1 RAs, applicable to next-gen peptides
Read More

Beyond treatment - the reality of living with a metabolic disease

Living with obesity, diabetes, and other metabolic disorders often means lifelong treatment — impacting not only health, but daily life.

Despite important medical progress, many therapies come with trade-offs, including tolerability challenges, inconvenience, and inconsistent adherence.

Advancing treatment approaches that better align with patient needs remains essential.

Read more about our clinical programs in obesity and diabetes

Driving the future of diabetes treatment

The Team Behind Diabetology

Diabetology is driven by a team of experienced scientists, healthcare innovators, and biotechnology professionals dedicated to improving diabetes treatment. Founded by experts in pharmaceutical research, drug delivery technologies, and healthcare entrepreneurship, the company combines strong scientific knowledge with commercial expertise. Together, the team focuses on developing innovative oral therapies that aim to transform how diabetes is managed worldwide.

DISCOVER MORE

Driving the future of diabetes treatment

The Team Behind Diabetology

Diabetology is driven by a team of experienced scientists, healthcare innovators, and biotechnology professionals dedicated to improving diabetes treatment. Founded by experts in pharmaceutical research, drug delivery technologies, and healthcare entrepreneurship, the company combines strong scientific knowledge with commercial expertise. Together, the team focuses on developing innovative oral therapies that aim to transform how diabetes is managed worldwide.

DISCOVER MORE

Publications & Press Releases

June 8, 2026

News

Breakthrough Clinical Data: Oraglutide Delivers Sustained Glucose Control for Six Days From a Single Oral Capsule — With No Reported Side Effects

Diabetology Limited presents first-in-human oral capsule, intestinally absorbed GLP1 RA data at ADA 86th Scientific Sessions...

Read More

NOvember 11, 2025

Publication

Perspectives on Commercialisation of Oral Insulin

The objective of this paper is to demonstrate that oral insulin is potentially close to being commercialized, in light of the fact that (i) the technical, safety, and pharmacological obstacles in developing an oral insulin for clinical use for diabetes can potentially be overcome, and (ii) there are players in the field that are moving an oral insulin formulation into advanced clinical trials.

Read More

July 5, 2025

Press Release

The Lifesciences Magazine’s New Issue Features the Most Innovative Biopharma Company Targeting Diabetes in 2024

Lifesciences Magazine: Battling Diabetes! Exclusive Interview with the Glen Travers (Co-founder of Diabetology Limited), Leading Biopharma Company Pushing Boundaries

Read More

Our Locations

Diabetology Limited

Charter Place,
23/27 Seaton place,
St Helier,
Jersey JE1 1JY,
Channel Islands

Diabetology (UK) Ltd

The London BioScience Innovation Centre
2 Royal College Street,
London
NW1 0NH
United Kingdom

Diabetology (International) Ltd

30 Federal St Subiaco
Western Australia
6008

Subscribe to our newsletter